Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Bonus News from MarketBeat Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsReported by Nathan Reiff. Published: 3/12/2026. 
Article Highlights - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of meaningful sales. Two smaller biotech companies are experiencing notable share price momentum thanks to their leading oncology medicines. Beyond their therapeutic promise, these drugs could help the firms move toward stability—escaping penny-stock or otherwise precarious status—and potentially toward long-term profitability. In both cases, considerable challenges remain, making these typical biotech investments high-risk but with the potential for outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle In 2023, Silicon Valley Bank collapsed in just 48 hours with panicked customers draining $42 billion in a single day, but it could be nothing compared to what's coming next—through Federal Reserve Docket No. OP-1670, the government is rolling out FedNow, an instant 24/7 payment hub that over 1,500 banks have already connected to, and when money moves at the speed of light, a modern bank run won't take days. By routing every transaction through a single centralized hub, the Fed is building the ultimate kill switch for the American banking system, and when the next financial crisis hits, the Federal Reserve could instantly freeze all transfers, withdrawals, and payments nationwide to protect the system, trapping your life savings inside. Get the 4 steps to Fed-proof your savings now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) performance, which has seen shares more than double. Still, with a consensus price target of $8.88, Wall Street expects more from IOVA shares—that target implies roughly 71% more upside. The main catalyst for Iovance's rally is its flagship drug, Amtagvi, a T‑cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States for melanoma since 2024 and is gaining momentum in sales, with additional approvals likely in the EU, U.K., and elsewhere. When administered with Proleukin, the company's IL‑2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's real potential may extend beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and could be effective against other tumor types as well. Some of Iovance's outperformance this year also reflects its Q4 2025 earnings report, released in late February, in which the company reported smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year-over-year. Iovance remains a relatively small company (around $2 billion in market value) and is still viewed cautiously by many analysts—about half of its roughly a dozen ratings are Hold or Sell. Risks are high: beyond the usual uncertainties for smaller biotech firms, Amtagvi's personalized nature makes it costly and complex to manufacture. That manufacturing complexity could limit Iovance's ability to generate consistent profits even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) has pulled back roughly 20% in March, but its YTD performance dwarfs Iovance's—IBRX shares are up nearly 300% in 2026 so far. Analysts' consensus price target of $13.60 is about 70% above the stock's current price, even after this major rally. ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares jumped after the EU regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide. Anktiva is already driving the company's revenue: ImmunityBio reported $113 million in sales in 2025, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring alternate designations. Despite the dramatic gains over the past several quarters, IBRX remains speculative and risky. ImmunityBio reported a full-year net loss of $351 million for 2025 as R&D spending remains substantial. Analysts are generally more bullish on IBRX than on Iovance—six of seven analysts rate the stock a Buy or equivalent—but downside risks are material.
| 
